Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study.

IF 1.8 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiology Research and Practice Pub Date : 2023-01-01 DOI:10.1155/2023/3197512

Troels Thim, Lars Jakobsen, Rebekka Vibjerg Jensen, Nicolaj Støttrup, Ashkan Eftekhari, Erik Lerkevang Grove, Sanne Bøjet Larsen, Jacob Thorsted Sørensen, Steen Carstensen, Sahar Amiri, Karsten Tange Veien, Evald Høj Christiansen, Christian Juhl Terkelsen, Michael Maeng, Steen Dalby Kristensen

{"title":"Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study.","authors":"Troels Thim, Lars Jakobsen, Rebekka Vibjerg Jensen, Nicolaj Støttrup, Ashkan Eftekhari, Erik Lerkevang Grove, Sanne Bøjet Larsen, Jacob Thorsted Sørensen, Steen Carstensen, Sahar Amiri, Karsten Tange Veien, Evald Høj Christiansen, Christian Juhl Terkelsen, Michael Maeng, Steen Dalby Kristensen","doi":"10.1155/2023/3197512","DOIUrl":null,"url":null,"abstract":"Background: Reversible P2Y12 inhibition can be obtained with cangrelor administered intravenously. More experience with cangrelor use in acute PCI with unknown bleeding risk is needed.Objectives: To describe real-world use of cangrelor including patient and procedure characteristics and patient outcomes.Methods: We performed a single-centre, retrospective, and observational study including all patients treated with cangrelor in relation to percutaneous coronary intervention at Aarhus University Hospital during the years 2016, 2017, and 2018. We recorded procedure indication and priority, the indications for cangrelor use, and patient outcomes within the first 48 hours after initiation of cangrelor treatment.Results: We treated 991 patients with cangrelor in the study period. Of these, 869 (87.7%) had an acute procedure priority. Among acute procedures, patients were mainly treated for STEMI (n = 723) and the remaining were treated for cardiac arrest and acute heart failure. Use of oral P2Y12 inhibitors prior to percutaneous coronary intervention was rare. Fatal bleeding events (n = 6) were only observed among patients undergoing acute procedures. Stent thrombosis was observed in two patients receiving acute treatment for STEMI. Thus, cangrelor can be used in relation to PCI under acute circumstances with advantages in terms of clinical management. The benefits and risks, in terms of patient outcomes, should ideally be assessed in randomized trials.","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2023 ","pages":"3197512"},"PeriodicalIF":1.8000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289876/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology Research and Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/3197512","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Reversible P2Y12 inhibition can be obtained with cangrelor administered intravenously. More experience with cangrelor use in acute PCI with unknown bleeding risk is needed.

Objectives: To describe real-world use of cangrelor including patient and procedure characteristics and patient outcomes.

Methods: We performed a single-centre, retrospective, and observational study including all patients treated with cangrelor in relation to percutaneous coronary intervention at Aarhus University Hospital during the years 2016, 2017, and 2018. We recorded procedure indication and priority, the indications for cangrelor use, and patient outcomes within the first 48 hours after initiation of cangrelor treatment.

Results: We treated 991 patients with cangrelor in the study period. Of these, 869 (87.7%) had an acute procedure priority. Among acute procedures, patients were mainly treated for STEMI (n = 723) and the remaining were treated for cardiac arrest and acute heart failure. Use of oral P2Y12 inhibitors prior to percutaneous coronary intervention was rare. Fatal bleeding events (n = 6) were only observed among patients undergoing acute procedures. Stent thrombosis was observed in two patients receiving acute treatment for STEMI. Thus, cangrelor can be used in relation to PCI under acute circumstances with advantages in terms of clinical management. The benefits and risks, in terms of patient outcomes, should ideally be assessed in randomized trials.

Abstract Image

查看原文本刊更多论文

康格乐作为经皮冠状动脉介入治疗的辅助治疗:一项单中心观察性研究。

背景:静脉给药康瑞洛可获得可逆的P2Y12抑制。在出血风险未知的急性PCI中使用康格洛的经验是必要的。目的:描述现实世界中康格洛的使用，包括患者和手术特点以及患者结果。方法:我们进行了一项单中心、回顾性和观察性研究，包括2016年、2017年和2018年在奥胡斯大学医院接受canrelor经皮冠状动脉介入治疗的所有患者。我们记录了手术适应症和优先级，使用康瑞洛的适应症，以及开始康瑞洛治疗后48小时内的患者结果。结果:在研究期间，我们治疗了991例患者。其中869例(87.7%)为急症优先。在急性手术中，患者主要治疗STEMI (n = 723)，其余患者治疗心脏骤停和急性心力衰竭。在经皮冠状动脉介入治疗前使用口服P2Y12抑制剂是罕见的。仅在接受急性手术的患者中观察到致命性出血事件(n = 6)。在接受STEMI急性治疗的2例患者中观察到支架血栓形成。因此，在急性情况下，canrelor可用于PCI，在临床管理方面具有优势。就患者结果而言，其益处和风险最好在随机试验中进行评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiology Research and Practice Medicine-Cardiology and Cardiovascular Medicine

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Cardiology Research and Practice is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies that focus on the diagnosis and treatment of cardiovascular disease. The journal welcomes submissions related to systemic hypertension, arrhythmia, congestive heart failure, valvular heart disease, vascular disease, congenital heart disease, and cardiomyopathy.